Evidence map›Paper›PMID 41862097›Full record

ArticleJournal of thrombosis and haemostasis : JTH2026

Plasma level of human epididymis protein 4 is associated with risk of future venous thromboembolism-the Trøndelag Health study.

Celina Janene Cathro, Ellen-Sofie Wulff Eilertsen, Therese H Nøst, Kristian D Hindberg, Weihong Tang, Weihua Guan, Aaron R Folsom, Christian Jonasson, Laurent Thomas, Kristian Hveem and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Celina Janene CathroThrombosis Research Group, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
Ellen-Sofie Wulff EilertsenThrombosis Research Group, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway; Division of Internal Medicine, Thrombosis Research Center, University Hospital of North Norway, Tromsø, Norway.
Therese H NøstDepartment of Public Health and Nursing, HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway; HUNT Research Center, Norwegian University of Science and Technology, Levanger, Norway; Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway; Department of Community Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
Kristian D HindbergDivision of Internal Medicine, Thrombosis Research Center, University Hospital of North Norway, Tromsø, Norway.
Weihong TangDivision of Epidemiology and Community Health, University of Minnesota, School of Public Health, Minneapolis, MN, USA.
Weihua GuanDivision of Biostatistics, University of Minnesota, School of Public Health, Minneapolis, MN, USA.
Aaron R FolsomDivision of Epidemiology and Community Health, University of Minnesota, School of Public Health, Minneapolis, MN, USA.
Christian JonassonHUNT Research Center, Norwegian University of Science and Technology, Levanger, Norway.
Laurent ThomasDepartment of Public Health and Nursing, HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; BioCore - Bioinformatics Core Facility, Norwegian University of Science and Technology, Trondheim, Norway; Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim, Norway.
Kristian HveemDepartment of Public Health and Nursing, HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway; HUNT Research Center, Norwegian University of Science and Technology, Levanger, Norway; Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway; Department of Research, St. Olavs Hospital, Trondheim, Norway.
Sigrid K BrækkanThrombosis Research Group, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway; Division of Internal Medicine, Thrombosis Research Center, University Hospital of North Norway, Tromsø, Norway. Electronic address: http://x.com/SBraekkan.
John-Bjarne HansenThrombosis Research Group, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway; Division of Internal Medicine, Thrombosis Research Center, University Hospital of North Norway, Tromsø, Norway.

Funding

Epidemiology of Venous Thrombosis & Pulmonary EmbolismR01HL059367 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI TANG, WEIHONG · 1998 to 2024
$11.8M
Identifying Proteomics Risk Markers for Abdominal Aortic AneurysmR01HL155209 · NHLBI · UNIVERSITY OF MINNESOTA · PI TANG, WEIHONG · 2021 to 2024
$3.1M
NHLBI NIH HHS R01 HL059367NHLBI NIH HHS R01 HL155209
6 · The paper itself

Abstract

backgroundPlasma human epididymis protein 4 (HE4) levels have been associated with the risk of future venous thromboembolism (VTE) in a proteome-wide study.

objectivesWe aimed to investigate whether plasma HE4 levels were (i) correlated with growth differentiation factor-15 (GDF-15), a marker of oxidative stress, (ii) associated with VTE risk after adjustment for potential confounders, and (iii) genetically regulated, as assessed by protein quantitative trait loci analyses.

methodsA case-cohort was derived from the Trøndelag Health Study (N = 50 800), including 294 incident VTE cases over 5 years of follow-up and a randomly sampled age- and sex-weighted subcohort (n = 1066). HE4 and GDF-15 levels were measured using an aptamer-based method in plasma collected at baseline. Weighted Cox regression was used to estimate hazard ratios for VTE, with 95% CIs based on quartiles (Q1-4) of HE4 levels.

resultsHE4 levels correlated with GDF-15 levels (r = .71; P = 3.42 × 10

conclusionHE4 levels were associated with an increased risk of future VTE after adjustment for major confounders and did not appear to be strongly genetically regulated. Our findings suggest that HE4 levels may reflect an underlying condition, eg, oxidative stress, that predisposes to VTE.

Indexed as

ProteinsVenous ThromboembolismAdultAgedBiomarkersFemaleGenetic Predisposition to DiseaseGrowth Differentiation Factor 15HumansIncidenceMaleMiddle AgedNorwayOxidative StressPolymorphism, Single NucleotideProportional Hazards ModelsBiomarkersGrowth Differentiation Factor 15ProteinsWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humandeep vein thrombosishuman epididymis protein 4plasmapulmonary embolismvenous thromboembolism

Identifiers

PMID41862097
PMCPMC13486973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.